<DOC>
	<DOCNO>NCT00263588</DOCNO>
	<brief_summary>Determine safe effective lapatinib use treat patient ErbB2 overexpressing breast cancer spread brain still progress even radiation treatment use WBRT ( whole brain radiotherapy ) SRS ( stereotactic radiosurgery ) brain . Lapatinib oral drug take every day . Tests safety efficacy perform every 4 week 8 week ( depend test ) course study .</brief_summary>
	<brief_title>Lapatinib Brain Metastases In ErbB2-Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Inclusion criterion : Signed Informed Consent ErbB2 ( HER2 ) overexpressing breast cancer . Brain lesion ( ) progressing . Prior treatment brain metastasis Whole Brain Radiotherapy ( WBR ) and/or Stereotactic Radiosurgery ( SRS ) . Prior treatment trastuzumab ( Herceptin ) , either alone combination chemotherapy . Cardiac ejection fraction ( LVEF ) within institutional range normal measure Echocardiogram . Able swallow oral medication . Adequate kidney liver function . Adequate bone marrow function . Exclusion criterion : Pregnant lactating female . Conditions would effect absorption oral drug . History immediate delay hypersensitivity reaction gadolinium contrast agent . Preexisting severe cerebral vascular disease , stroke involve major vessel . Serious medical psychiatric disorder would interfere patient 's safety inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>breast cancer brain metastasis ErbB2 positive HER2 positive</keyword>
</DOC>